Iomai reports success with traveler’s diarrhea patch

Iomai has racked up more positive data for its vaccine patch to prevent traveler's diarrhea. A new study details that only three of 59 volunteers who used the patch experienced a severe or moderate bout of diarrhea compared to 24 of 111 who were given a placebo. The three patch users who did get sick reported that the bout lasted for only a half day. No side effects were reported.

"These results suggest that the Iomai patch has the potential to fundamentally change the way we approach prevention of this disease, an ailment against which we now have very few weapons," says Dr. Herber L. DuPont, professor and director of the Center for Infectious Diseases at The University of Texas School of Public Health. 

Iomai recently agreed to a takeover by Intercell.

- here's Iomai's release
- read the story in CTV

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.